S-1 in colorectal cancer: A new standard of care?

摘要

Substantial advances have been made in palliative therapy for metastatic colorectal cancer in the past 15 years. These advances were driven by the introduction of various cytotoxic and biological agents into standard treatment algorithms for the disease. The list of cytotoxic agents (ie, conventional chemotherapy) includes fluoro-pyrimidines (intravenous fluorouracil or oral fluorouracil prodrugs such as capecitabine), oxaliplatin, and irinotecan, which are commonly combined in clinical practice. Patients have an increased chance of survival if they have access to all available cytotoxic agents. The addition of biological agents like bevacizumab and the antibodies against EGFR in KRAS wild-type colorectal cancers, cetuximab and paniturnumab, have further improved outcomes by a few months.